These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28028292)

  • 1. Glypican-3 is useful but not superior to Hep Par 1 in differentiating hepatocellular carcinoma from other liver tumours.
    Pour AM; Masir N; Rose IM
    Malays J Pathol; 2016 Dec; 38(3):229-233. PubMed ID: 28028292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hep par-1: a novel immunohistochemical marker for differentiating hepatocellular carcinoma from metastatic carcinoma.
    Hanif R; Mansoor S
    J Coll Physicians Surg Pak; 2014 Mar; 24(3):186-9. PubMed ID: 24613115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization of antihepatocyte clone OCH1E5 (Hep Par 1) in histological evaluation of liver tumors.
    Amarapurkar AD; Rege JD; Joshi AS; Vaiphei K; Amarapurkar DN
    Indian J Pathol Microbiol; 2006 Jul; 49(3):341-4. PubMed ID: 17001880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma.
    Shiran MS; Isa MR; Sherina MS; Rampal L; Hairuszah I; Sabariah AR
    Malays J Pathol; 2006 Dec; 28(2):87-92. PubMed ID: 18376797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of RNA-binding protein LIN28 in classic gastric hepatoid carcinomas, gastric fetal type gastrointestinal adenocarcinomas, and hepatocellular carcinomas: An immunohistochemical study with comparison to SALL4, alpha-fetoprotein, glypican-3, and Hep Par1.
    Zhao M; Sun L; Lai JZ; Shi H; Mei K; He X; Jin X; Lai J; Cao D
    Pathol Res Pract; 2018 Oct; 214(10):1707-1712. PubMed ID: 30196987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamine synthetase, heat shock protein-70, and glypican-3 in intrahepatic cholangiocarcinoma and tumors metastatic to liver.
    Lagana SM; Moreira RK; Remotti HE; Bao F
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):254-7. PubMed ID: 22914614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study.
    Zhang L; Liu H; Sun L; Li N; Ding H; Zheng J
    Acta Histochem; 2012 Oct; 114(6):547-52. PubMed ID: 22119409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.
    Ibrahim TR; Abdel-Raouf SM
    Pathol Oncol Res; 2015 Apr; 21(2):379-87. PubMed ID: 25108409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
    Nassar A; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma.
    Leong AS; Sormunen RT; Tsui WM; Liew CT
    Histopathology; 1998 Oct; 33(4):318-24. PubMed ID: 9822920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Significance of glypican-3 immunohistochemistry in diagnosis of hepatocellular carcinoma].
    Yip YC; Wang FH; Vong HT; Zhang M; Wen JM
    Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):626-9. PubMed ID: 22177248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma.
    Kakar S; Muir T; Murphy LM; Lloyd RV; Burgart LJ
    Am J Clin Pathol; 2003 Mar; 119(3):361-6. PubMed ID: 12645337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma.
    Lau SK; Prakash S; Geller SA; Alsabeh R
    Hum Pathol; 2002 Dec; 33(12):1175-81. PubMed ID: 12514785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bile salt export pump: a sensitive and specific immunohistochemical marker of hepatocellular carcinoma.
    Lagana SM; Salomao M; Remotti HE; Knisely AS; Moreira RK
    Histopathology; 2015 Mar; 66(4):598-602. PubMed ID: 25378077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma].
    Dong H; Cong WL; Zhu ZZ; Wang B; Xian ZH; Yu H
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):702-5. PubMed ID: 19173916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
    Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
    J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein.
    Chu PG; Ishizawa S; Wu E; Weiss LM
    Am J Surg Pathol; 2002 Aug; 26(8):978-88. PubMed ID: 12170084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study on Diagnostic Values of Astrocyte Elevated Gene 1 (AEG-1) and Glypican 3 (GPC-3) in Hepatocellular Carcinoma.
    Cao W; Sharma M; Imam R; Yu J
    Am J Clin Pathol; 2019 Oct; 152(5):647-655. PubMed ID: 31305883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma.
    Lagana SM; Salomao M; Bao F; Moreira RK; Lefkowitch JH; Remotti HE
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):170-6. PubMed ID: 22914605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of immunohistochemical markers for differential diagnosis of hepatocelluar carcinoma and cholangiocarcinoma.
    Ryu HS; Lee K; Shin E; Kim SH; Jing J; Jung HY; Lee H; Jang JJ
    Tumori; 2012; 98(4):478-84. PubMed ID: 23052165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.